Used in targeted cancer therapies, particularly for tumors driven by RET gene fusions or mutations. It serves as a reference in the development of monoclonal antibody treatments, helping evaluate binding affinity and functional inhibition of the RET receptor. Commonly applied in preclinical research to benchmark new anti-RET antibodies and assess their efficacy in blocking RET signaling pathways. Also utilized in diagnostic assay development to detect RET expression in tumor samples. Supports drug discovery efforts in non-small cell lung cancer, thyroid cancers, and other RET-altered malignancies.